These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 12865802

  • 21. Posttransplantation lymphoproliferative disorders in renal transplant recipients: report of over 20 years of experience.
    Saadat A, Einollahi B, Ahmadzad-Asl MA, Moradi M, Nafar M, Pourfarziani V, Firoozan A, Porrezagholi F, Davoudi F.
    Transplant Proc; 2007 May; 39(4):1071-3. PubMed ID: 17524894
    [Abstract] [Full Text] [Related]

  • 22. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 23. Posttransplant lymphoproliferative disorders in transplant recipients.
    Timurağaoğlu A, Uğur-Bilgin A, Colak D, Tuncer M, Gölbaşi I, Hazar V, Kiliçarsłan B, Undar L, Demirbaş A.
    Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
    [Abstract] [Full Text] [Related]

  • 24. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
    Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, Shaw L, Wasik MA.
    Transplantation; 2003 May 27; 75(10):1710-7. PubMed ID: 12777861
    [Abstract] [Full Text] [Related]

  • 25. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B.
    Ann Hematol; 2006 Jul 27; 85(7):478-84. PubMed ID: 16586109
    [Abstract] [Full Text] [Related]

  • 26. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F, Kunitake H, Laks H, Odim J.
    Pediatr Transplant; 2006 Feb 27; 10(1):60-6. PubMed ID: 16499589
    [Abstract] [Full Text] [Related]

  • 27. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ, Bayerl MG, Sandhaus LM, Sebastian S, Rehder CW, Routbort M, Lagoo AS, Szabolcs P, Chiu J, Comito M, Buckley PJ.
    Am J Surg Pathol; 2006 Mar 27; 30(3):328-36. PubMed ID: 16538052
    [Abstract] [Full Text] [Related]

  • 28. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML, Swinnen LJ, Plaisance KT, Schnell C, Grogan TM, Schneider BG, Southwest Oncology Group.
    Transplantation; 2003 Sep 27; 76(6):959-64. PubMed ID: 14508361
    [Abstract] [Full Text] [Related]

  • 29. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G, Döhler B, Collaborative Transplant Study.
    Transplantation; 2009 Mar 27; 87(6):795-802. PubMed ID: 19300179
    [Abstract] [Full Text] [Related]

  • 30. Malignancies after kidney transplantation.
    Rascente M, Pisani F, Barletta A, D'Angelo M, Giammaria A, Parzanese I, Rizza V, Iaria G, Famulari A.
    Transplant Proc; 2005 Mar 27; 37(6):2529-31. PubMed ID: 16182735
    [Abstract] [Full Text] [Related]

  • 31. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.
    Cleper R, Ben Shalom E, Landau D, Weissman I, Krause I, Konen O, Rahamimov R, Mor E, Bar-Nathan N, Frishberg Y, Davidovits M.
    Pediatr Transplant; 2012 Sep 27; 16(6):619-26. PubMed ID: 22708682
    [Abstract] [Full Text] [Related]

  • 32. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E, Jones M, Hourigan MJ, Johnson DW, Gill DS, Isbel N, Hawley CM, Marlton P, Gandhi MK, Campbell SB, Mollee P.
    Nephrol Dial Transplant; 2015 Oct 27; 30(10):1774-9. PubMed ID: 26188340
    [Abstract] [Full Text] [Related]

  • 33. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients.
    Libertiny G, Watson CJ, Gray DW, Welsh KI, Morris PJ.
    Br J Surg; 2001 Oct 27; 88(10):1330-4. PubMed ID: 11578286
    [Abstract] [Full Text] [Related]

  • 34. A single-centre experience of post-renal transplant lymphoproliferative disorder.
    Herzig KA, Juffs HG, Norris D, Brown AM, Gill D, Hawley CM, Cobcroft R, Petrie JB, Marlton P, Thomson D, Campbell SB, Nicol DL, Johnson DW.
    Transpl Int; 2003 Jul 27; 16(7):529-36. PubMed ID: 12734646
    [Abstract] [Full Text] [Related]

  • 35. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder.
    Cullis B, D'Souza R, McCullagh P, Harries S, Nicholls A, Lee R, Bingham C.
    Am J Kidney Dis; 2006 May 27; 47(5):e67-72. PubMed ID: 16632009
    [Abstract] [Full Text] [Related]

  • 36. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC, Curtis JL, Szmuszkovicz JR, Horn MV, Ford HR, Woo MS, Wang KS.
    J Pediatr Surg; 2008 Dec 27; 43(12):2174-7. PubMed ID: 19040929
    [Abstract] [Full Text] [Related]

  • 37. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.
    McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, Jevnikar AM, Rizkalla KS.
    Liver Transpl; 2000 Sep 27; 6(5):570-4. PubMed ID: 10980055
    [Abstract] [Full Text] [Related]

  • 38. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients.
    Preiksaitis JK, Keay S.
    Clin Infect Dis; 2001 Jul 01; 33 Suppl 1():S38-46. PubMed ID: 11389521
    [Abstract] [Full Text] [Related]

  • 39. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA.
    Clin Transplant; 2006 Jul 01; 20(3):389-93. PubMed ID: 16824159
    [Abstract] [Full Text] [Related]

  • 40. Outcomes of kidney retransplantation in recipients with prior posttransplant lymphoproliferative disorders: An analysis of the 2000-2019 UNOS/OPTN database.
    Leeaphorn N, Thongprayoon C, Chewcharat A, Hansrivijit P, Jadlowiec CC, Cummings LS, Katari S, Mao SA, Mao MA, Cheungpasitporn W.
    Am J Transplant; 2021 Feb 01; 21(2):846-853. PubMed ID: 33128832
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.